Skip to main content
Quantum Genomics logo

Quantum Genomics — Investor Relations & Filings

Ticker · ALQGC ISIN · FR0011648971 LEI · 969500TFCD8K9RPM9K97 PA Manufacturing
Open in API
Filings indexed 341 across all filing types
Latest filing 2014-08-29 Regulatory Filings
Country FR France
Listing PA ALQGC

About Quantum Genomics

https://quantum-genomics.com/

Quantum Genomics is a biopharmaceutical company focused on developing a new class of medications for cardiovascular diseases with high unmet medical needs, such as difficult-to-treat or resistant hypertension and heart failure. The company's core research is based on a breakthrough therapeutic approach involving the inhibition of Brain Aminopeptidase A (BAPA). Its lead drug candidate, firibastat, is a first-in-class BAPA inhibitor designed to offer a novel treatment mechanism for managing these conditions.

Recent filings

Filing Released Lang Actions
Apport complémentaire au contrat de liquidité
Regulatory Filings Classification · 99% confidence The document is a short announcement dated August 29, 2014, detailing a 'complémentary contribution' (apport complémentaire) of 20,000 euros to a liquidity contract (contrat de liquidité) managed by Aurel BGC. This action relates to the company's capital management or financing activities, specifically concerning market liquidity maintenance. This fits best under 'Capital/Financing Update' (CAP), as it is a direct action affecting the company's financial structure or market support mechanisms, rather than a general regulatory filing (RNS) or a dividend announcement (DIV). Given the short length and specific financial action, CAP is the most appropriate classification.
2014-08-29 French
Professor Pierre Corvol appointed Chairman of the Scientific Advisory Board of Quantum Genomics
Board/Management Information Classification · 99% confidence The document announces the appointment of Professor Pierre Corvol as Chairman of the Scientific Advisory Board of Quantum Genomics. This is a specific announcement regarding a change in the company's advisory structure and key personnel, rather than a financial report (like 10-K, ER, IR) or a general regulatory filing. It directly relates to the composition and expertise guiding the company's direction, fitting best under Board/Management Information (MANG), which covers changes in senior personnel and governance structure elements like advisory boards.
2014-07-08 English
Bilan semestriel du contrat de liquidité au 30 juin 2014
Capital/Financing Update Classification · 99% confidence The document is titled "Bilan semestriel du contrat de liquidité au 30 juin 2014" (Semi-annual balance sheet of the liquidity contract as of June 30, 2014). It reports on the status of a liquidity contract (likely related to share stabilization or market making) at a specific semi-annual date (June 30, 2014). This type of report, detailing financial arrangements or specific contractual balances for a defined period shorter than a full year, aligns best with the definition of an Interim/Quarterly Report (IR), as it is a periodic financial/contractual update. It is not a full 10-K, an earnings release (ER), or a general regulatory filing (RNS). Given the semi-annual nature, IR is the most appropriate fit among the provided options.
2014-07-02 French
Quantum Genomics a présenté les résultats définitifs des études cliniques de phase I menées avec son produit QGC001 à l'occasion du congrès commun des Sociétés Européenne et Internationale d'Hypertens
Regulatory Filings Classification · 95% confidence The document is a press release dated June 18, 2014, announcing the presentation of definitive Phase I clinical trial results for the molecule QGC001 at a medical congress (HYPERTENSION 2014). It details the scientific findings (antihypertensive agent, BAPAI inhibitors) and outlines upcoming investor/industry events (BIO convention, French Life Sciences Days). This content is characteristic of an announcement providing updates on scientific progress and future investor engagement, rather than a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). Since it is an announcement about scientific/clinical progress and upcoming investor meetings, it fits best under the general category of Investor Presentation (IP) or a Regulatory Filing (RNS) if no better fit exists. Given the focus on presenting clinical data and upcoming investor conferences, 'Investor Presentation' (IP) is a strong candidate, although it is structured as a press release. However, since it is primarily an announcement of scientific results and future corporate visibility events, and not a formal presentation deck, 'Regulatory Filings' (RNS) serves as a safe general category for non-standard corporate updates, or 'IP' if we interpret the presentation of results as an investor-focused communication. Given the context of presenting clinical data to the market, 'Investor Presentation' (IP) is the most specific fit for communicating scientific milestones to investors, even if the format is a press release announcing the presentation.
2014-06-18 French
Quantum Genomics strengthens its management team by appointing Marc Karako, Chief Financial Officer, and Jean-Philippe Milon, Chief Operating Officer
Board/Management Information Classification · 99% confidence The document explicitly announces the appointment of two key senior executives: Marc Karako as Chief Financial Officer (CFO) and Jean-Philippe Milon as Chief Operating Officer (COO). This content directly aligns with the definition of Board/Management Information, which covers announcements of changes in senior management.
2014-05-15 English
Quantum Genomics renforce son management à travers la nomination de Marc Karako, Vice-Président Finance, et Jean-Philippe Milon, Vice-Président Opérations
Board/Management Information Classification · 100% confidence The document explicitly announces the appointment of two new senior executives: Marc Karako as Vice-President Finance and Jean-Philippe Milon as Vice-President Operations. This content directly matches the definition for Board/Management Information, which covers announcements of changes in the company's board of directors or senior management.
2014-05-14 French

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.